These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30275274)

  • 1. Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study.
    Eshet Y; Baruch EN; Shapira-Frommer R; Steinberg-Silman Y; Kuznetsov T; Ben-Betzalel G; Daher S; Gluck I; Asher N; Apter S; Schachter J; Bar J; Boursi B; Markel G
    Cancer Immunol Res; 2018 Dec; 6(12):1453-1458. PubMed ID: 30275274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy.
    Prasanna T; McNeil CM; Nielsen T; Parkin D
    Immunotherapy; 2018 Mar; 10(3):171-175. PubMed ID: 29370723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
    Hoadley A; Sandanayake N; Long GV
    Ann Oncol; 2017 Feb; 28(2):434-435. PubMed ID: 27864215
    [No Abstract]   [Full Text] [Related]  

  • 5. Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors.
    Satish D; Lin IH; Flory J; Gerdes H; Postow MA; Faleck DM
    Oncologist; 2023 Dec; 28(12):1085-1093. PubMed ID: 37285223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
    Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
    Tandon P; Bourassa-Blanchette S; Bishay K; Parlow S; Laurie SA; McCurdy JD
    J Immunother; 2018 Apr; 41(3):101-108. PubMed ID: 29401166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    Reddy SB; Possick JD; Kluger HM; Galan A; Han D
    J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy.
    Ezponda Casajús A; Calvo Imirizaldu M; de Torres Tajes JP; García-Baizán A; Castañón Álvarez E; Cano Rafart D; Vivas Pérez I; Bastarrika Alemañ G
    Radiologia (Engl Ed); 2020; 62(2):131-138. PubMed ID: 31405549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
    Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
    J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diarrhoea during checkpoint blockade, not always colitis.
    Koldenhof JJ; Suijkerbuijk KPM
    Eur J Cancer; 2017 Dec; 87():216-218. PubMed ID: 28993041
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].
    Neubauer A
    Internist (Berl); 2017 Apr; 58(4):409-423. PubMed ID: 28303311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
    Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
    Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies.
    Chen JH; Pezhouh MK; Lauwers GY; Masia R
    Am J Surg Pathol; 2017 May; 41(5):643-654. PubMed ID: 28296676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
    Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superimposed Clostridium difficile Infection During Checkpoint Inhibitor Immunotherapy-induced Colitis.
    Babacan NA; Tanvetyanon T
    J Immunother; 2019; 42(9):350-353. PubMed ID: 31107370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.